Welcome to GenPrice! Check out our latest updates.

Shopping Cart (0)

Your cart is empty

Add some products to get started!

Atorvastatin (calcium hydrate)

Atorvastatin calcium salt trihydrate is a drug belonging to the statin class of drugs used to lower blood cholesterol levels. Atorvastatin calcium salt trihydrate has unique chemical properties that make it an effective tool in controlling high levels of low-density lipoprotein (LDL) cholesterol and triglycerides in the body, reducing the risk of heart attack and stroke. Atorvastatin calcium salt trihydrate works by inhibiting HMG-CoA reductase, the enzyme responsible for producing cholesterol in the liver.

Product Specifications

CAS Number

[344423-98-9]

UNSPSC

12352200

Hazard Statement

H351, H360

Target

HMG-CoA Reductase (HMGCR)

Type

Biochemical Assay Reagents

Related Pathways

Metabolic Enzyme/Protease

Field of Research

Others; Cardiovascular Disease

Assay Protocol

https://www.medchemexpress.com/atorvastatin-calcium-hydrate.html

Purity

99.83

Solubility

DMSO : ≥ 100 mg/mL

Smiles

O=C(C(C(C1=CC=CC=C1)=C(C2=CC=C(F)C=C2)N3CC[C@@H](O)C[C@@H](O)CC(O)=O)=C3C(C)C)NC4=CC=CC=C4.[1/2].[3/2].[Ca].O

Molecular Formula

C33H35FN2O5.1/2Ca.3/2H2O

Molecular Weight

605.71

Precautions

H351, H360

References & Citations

Eur J Med Chem. 2024 Dec 5.|Acta Pharmacol Sin. 2024 Mar 8.|Arterioscler Thromb Vasc Biol. 2022 May;42(5):644-658.|Biomed Pharmacother. 2023 Aug 12;166:115323.|Biotechnol Bioeng. 2021 Sep 3.|Cancer Lett. 2022 Oct 19;215976.|Cell Cycle. 2019 Dec;18(23):3337-3350.|Cell Cycle. 2021 Sep 8;1-14.|Endocrinology. 2022 May 18;bqac076.|Eur J Pharmacol. 2023 Aug 1;956:175938.|Eur J Pharmacol. 2023 Dec 21:176261.|Exp Cell Res. 2023 Oct 23:113829.|Front Cell Dev Biol. 2022 Mar 3;10:806081.|Inflammation. 2024 Oct 31.|Int J Mol Sci. 2023 Apr 19, 24(8), 7492.|J Appl Toxicol. 2024 Apr 19|J Appl Toxicol. 2024 Apr 19.|J Mol Neurosci. 2021 Sep 26.|J Nat Prod. 2022 Jun 24.|J Neuroimmunol. 2020 Oct 24;350:577429.|J Tradit Complement Med. 2024 Mar 29.|Med Gas Res. 2024 March 28.|MedComm. 2024 Aug 31.|Mol Cell. 2021 Jul 1;81(13):2736-2751.e8.|Naunyn Schmiedebergs Arch Pharmacol. 2023 Jun 8.|Oncogene. 2022 Oct 31.|Orebro University. 2024.|Phytomedicine. 2023 Jul 26;119:154997.|Proteomics. 2023 May 4;e2300041.|Research Square Preprint. 2021 Dec.|Research Square Preprint. 2022 Jun.|Research Square Preprint. 2024 Apr 9.|Sci Rep. 2020 Jan 28;10(1):1308.|Signal Transduct Target Ther. 2023 Dec 25;8(1):457.|Adv Sci (Weinh). 2024 Jul 5:e2403451.|bioRxiv. 2024 Jul 3:2024.07.01.601474.|Cell Death Dis. 2021 May 13;12(5):482.|Endocrinology. 2018 May 1;159(5):2008-2021.|Free Radic Biol Med. 2024 May 2:S0891-5849(24)00435-0.|Front Bioeng Biotechnol. 2022 Mar 17;10:826093.|Pharmaceutics. 2022, 14(1), 176.

Shipping Conditions

Room Temperature

Storage Conditions

4°C (Powder, sealed storage, away from moisture)

Scientific Category

Biochemical Assay Reagents

Clinical Information

Launched

Citation 01

Eur J Med Chem. 2024 Dec 5:279:116842.|Acta Diabetol. 2025 Mar 27.|Acta Pharmacol Sin. 2024 Jun;45 (6) :1316-1320.|Arterioscler Thromb Vasc Biol. 2022 May;42 (5) :644-658.|Biomed Pharmacother. 2023 Oct:166:115323.|Biotechnol Bioeng. 2021 Dec;118 (12) :4687-4698.|Cancer Lett. 2023 Jan 1:552:215976.|Cell Cycle. 2019 Dec;18 (23) :3337-3350.|Cell Cycle. 2021 Oct;20 (20) :2160-2173.|Chem Biol Interact. 2025 Oct 22:420:111671.|Clin Pharmacol Ther. 2025 Jul 14.|Emerg Microbes Infect. 2025 Dec;14 (1) :2470371.|Endocrinology. 2022 Jul 1;163 (7) :bqac076.|Environ Sci Technol Lett. 2025 Apr 8.|Eur J Pharmacol. 2023 Oct 5:956:175938.|Eur J Pharmacol. 2024 Feb 5:964:176261.|Eur J Pharmacol. 2025 Feb 5:177357.|Exp Cell Res. 2023 Dec 15;433 (2) :113829.|Exp Neurol. 2025 May 16:115305.|FEBS Open Bio. 2025 Aug 8.|Front Cell Dev Biol. 2022 Mar 3;10:806081.|Front Pharmacol. 2025 Apr 30:16:1573032.|Inflammation. 2024 Oct 31.|Int Immunopharmacol. 2025 Dec 3:166:115644.|Int J Mol Sci. 2023 Apr 19;24 (8) :7492.|J Appl Toxicol. 2024 Apr 19|J Appl Toxicol. 2024 Aug;44 (8) :1198-1213.|J Mol Neurosci. 2022 Mar;72 (3) :565-573.|J Nat Prod. 2022 Jul 22;85 (7) :1738-1750.|J Neuroimmunol. 2020 Oct 24:350:577429.|J Tradit Complement Med. 2024 Mar 29.|Life Sci. 2025 Jun 1:370:123571.|Med Gas Res. 2025 Mar 1;15 (1) :148-155.|MedComm (2020) . 2024 Aug 31;5 (9) :e681.|Mol Cell. 2021 Jul 1;81 (13) :2736-2751.e8.|Nat Aging. 2025 Aug 26.|Naunyn Schmiedebergs Arch Pharmacol. 2023 Dec;396 (12) :3659-3670.|Oncogene. 2022 Dec;41 (49) :5266-5278.|Oncologie. 2025 May 26.|Orebro University. 2024.|Phytomedicine. 2023 Jul 26;119:154997.|Phytomedicine. 2025 Jul:142:156713.|Phytomedicine. 2025 Oct:146:157128.|Proteomics. 2023 Aug;23 (16) :e2300041.|Research Square Preprint. 2021 Dec.|Research Square Preprint. 2022 Jun.|Research Square Preprint. 2024 Apr 9.|Sci Rep. 2020 Jan 28;10 (1) :1308.|Signal Transduct Target Ther. 2023 Dec 25;8 (1) :457.|Signal Transduct Target Ther. 2025 Nov 12;10 (1) :366.|SSRN. 2025 Apr 9.

Available Sizes

Curated Selection

Explore Other Products

Discover premium biology products from our extensive collection of 20M+ items

FITC Anti-Mouse CD11c Antibody
MBS4514362-01 0.025 mg

FITC Anti-Mouse CD11c Antibody

Ask
View Details
FITC Anti-Mouse CD11c Antibody
MBS4514362-02 0.05 mg

FITC Anti-Mouse CD11c Antibody

Ask
View Details
FITC Anti-Mouse CD11c Antibody
MBS4514362-03 0.1 mg

FITC Anti-Mouse CD11c Antibody

Ask
View Details
FITC Anti-Mouse CD11c Antibody
MBS4514362-04 5x 0.1 mg

FITC Anti-Mouse CD11c Antibody

Ask
View Details
Chicken Decoy Receptor 3 ELISA Kit
MBS7264660-01 48 Well

Chicken Decoy Receptor 3 ELISA Kit

Ask
View Details
Chicken Decoy Receptor 3 ELISA Kit
MBS7264660-02 96 Well

Chicken Decoy Receptor 3 ELISA Kit

Ask
View Details